The LRA’s Forum for Discovery: Sharing the Latest News in Lupus Research
The Lupus Research Alliance (LRA) held our annual scientific conference, the Forum for Discovery, online in true 2020 fashion. More than 150 funded investigators, scientific advisors, and partners from the pharmaceutical and biotech industries logged on from their computers around the world to hear about new discoveries from LRA-funded researchers. LRA President Ken Farber emphasized […]
Two Lupus Therapeutics Studies Report Positive Results at 2019 ACR/ARP Annual Meeting
November 12, 2019 Two positive clinical studies presented at the 2019 ACR/ARP Annual Meeting were conducted through the Lupus Clinical Investigators Network (LuCIN) formed and managed by Lupus Therapeutics, an affiliate of the Lupus Research Alliance. Results of both studies hold promise to improve how physicians can better monitor lupus patients’ symptoms and disease activity. […]
LRA’s Visionary Strategy to Turn Lupus Complexity to its Cure
July 15, 2021 Dear Friends, With much excitement, we introduce our new overarching approach to fulfilling LRA’s mission: Turning Complexity to Cure. Our goal is to involve the lupus community and beyond in our strategy to turn the core problem of lupus – its heterogeneity – how much it differs from person to person – into its solution through […]
LRA-BMS Accelerator Awards (BMS)
The LRA-BMS Accelerator Award ($300,000 for 2 years) is a collaborative project with sponsoring partner Bristol Myers Squibb supporting research on understanding human lupus heterogeneity and identifying novel biomarkers. If you are a researcher and would like to learn more about our funded research please click here.
Existing Cancer Drug May Lower Inflammation in Autoimmune Diseases Like Lupus
December 14, 2020 In a recent study published in the Journal of Immunology, LRA-funded researcher Dr. John Zhang at Medical University of South Carolina found that a protein called Fli-1 causes immune cells to produce a molecule that causes inflammation. When Fli-1 was hindered by the chemotherapeutic drug camptothecin, immune cells produced fewer inflammatory molecules. […]
New CDC Study Estimates 204,295 Americans Have Lupus
January 29, 2021 According to a new analysis funded by the Centers for Disease Control and Prevention, about 204,295 Americans have systemic lupus erythematosus (SLE), based on strict criteria for diagnosis by the American College of Rheumatology. These data, however, do not include cutaneous lupus. Based on an analysis of five studies, the national estimate […]
Diversity in Lupus Research Career Development Award
The Diversity in Lupus Research Career Development Award ($600,000 over four years) supports outstanding early-career underrepresented minority scientists to establish a competitive independent research program in the lupus research area. 2022 Award
Lupus Research Update
Lupus Research Update Volume 1 | 2023 Lupus Research Update Volume 3 | 2022 Lupus Research Update Volume 2 | 2022 Lupus Research Update Volume 1 | 2022 Lupus Research Update Volume 3 | 2021 Lupus Research Update Volume 2 |2021 COVID-19 Vaccines and the Lupus Community – read more The Power of Advocacy – […]
Recent Lupus Research Breakthroughs
Pursuing Promising Areas Of Lupus Scientific Inquiry A Highlight Of The Year’s Breakthroughs Throughout the year, the Lupus Research Alliance (LRA) funded the world’s most pioneering lupus research, pursued bold initiatives, and made tremendous gains! The brilliant scientists looking at lupus from every conceivable facet made new and important discoveries. These minds—the world’s best and […]
The Lupus Research Alliance Partners with the National Kidney Foundation to Offer Course to Healthcare Professionals
November 12, 2019 The Lupus Research Alliance (LRA) is pleased to announce a new collaboration with the National Kidney Foundation (NKF) on a free course for healthcare professionals about ways to better diagnose, monitor and treat patients with systemic lupus erythematosus (SLE) and lupus nephritis. The online course is critically important because as the community […]